Shares of Humana Inc. (NYSE:HUM – Get Free Report) reached a new 52-week high during trading on Monday after Royal Bank Of Canada upgraded the stock from a sector perform rating to an outperform rating. Royal Bank Of Canada now has a $563.00 price target on the stock, up from their previous price target of $415.00. Humana traded as high as $458.00 and last traded at $457.73, with a volume of 7,160 shares trading hands. The stock had previously closed at $450.00.
HUM has been the subject of a number of other research reports. UBS Group raised their price objective on shares of Humana from $405.00 to $495.00 and gave the stock a “neutral” rating in a research note on Monday, October 12th. Morgan Stanley raised Humana from an “underweight” rating to an “overweight” rating in a research note on Friday, October 9th. Mizuho upped their price objective on shares of Humana from $468.00 to $495.00 and gave the company an “outperform” rating in a research note on Tuesday, October 13th. Leerink Partners raised shares of Humana from a “market perform” rating to an “outperform” rating and set a $513.00 target price for the company in a research note on Thursday, July 30th. Finally, JPMorgan Chase & Co. upped their target price on Humana from $393.00 to $484.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 10th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $482.96.
View Our Latest Analysis on Humana
Insider Transactions at Humana
In other Humana news, insider Joseph Ventura sold 5,495 shares of the business’s stock in a transaction dated Monday, November 9th. The stock was sold at an average price of $433.85, for a total value of $2,384,005.75. Following the completion of the sale, the insider owned 21,910 shares of the company’s stock, valued at $9,505,653.50. The trade was a 20.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.20% of the company’s stock.
Institutional Investors Weigh In On Humana
A number of large investors have recently added to or reduced their stakes in HUM. BlackRock Inc. acquired a new stake in shares of Humana in the second quarter worth $4,138,160,000. State Street Corp grew its stake in Humana by 1.6% in the 3rd quarter. State Street Corp now owns 5,543,942 shares of the insurance provider’s stock valued at $2,115,402,000 after buying an additional 86,870 shares during the last quarter. Pzena Investment Management LLC acquired a new position in Humana in the 2nd quarter valued at $1,749,014,000. Assenagon Asset Management S.A. raised its holdings in Humana by 20,126.8% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,255,479 shares of the insurance provider’s stock worth $479,053,000 after acquiring an additional 1,249,272 shares during the period. Finally, Legal & General Group Plc bought a new position in Humana in the 2nd quarter worth $329,760,000. Institutional investors own 92.38% of the company’s stock.
Humana Stock Performance
The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.65 and a current ratio of 1.65. The stock’s 50-day simple moving average is $408.53 and its two-hundred day simple moving average is $316.91. The stock has a market cap of $54.54 billion, a price-to-earnings ratio of 44.06, a price-to-earnings-growth ratio of 2.14 and a beta of 0.65.
Humana (NYSE:HUM – Get Free Report) last posted its quarterly earnings data on Friday, November 6th. The insurance provider reported ($0.70) EPS for the quarter, topping analysts’ consensus estimates of ($1.00) by $0.30. Humana had a return on equity of 8.50% and a net margin of 0.81%. The business had revenue of $41.16 billion for the quarter, compared to analyst estimates of $40.87 billion. During the same period in the previous year, the company posted $3.24 earnings per share. The firm’s revenue for the quarter was up 26.1% on a year-over-year basis. Humana has set its FY 2026 guidance at 9.500- EPS. Analysts forecast that Humana Inc. will post 9.66 earnings per share for the current year.
Humana Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 29th. Stockholders of record on Thursday, December 24th will be given a $0.8850 dividend. This represents a $3.54 annualized dividend and a dividend yield of 0.8%. The ex-dividend date of this dividend is Thursday, December 24th. Humana’s dividend payout ratio is currently 34.44%.
About Humana
Humana Inc. is a U.S. health and wellness company that provides health insurance and healthcare services. Its insurance offerings include Medicare Advantage, Medicare Supplement and prescription drug plans, as well as Medicaid and employer-sponsored plans. The company also provides care through CenterWell, its healthcare services brand, which includes primary care, home health and pharmacy services. Its insurance and care offerings are available in markets across the United States, with availability varying by product and location.
Featured Articles
- Five stocks we like better than Humana
- Meta’s Access to Capital Remains Strong, But Borrowing Is Becoming More Expensive
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.
